{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P01308",
      "entity_text" : "insulin",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ00779",
      "entity_text" : "SGLT2i",
      "entity_type" : "protein"
    },
    "hypothesis_information" : true
  },
  "verbose_text" : "Evidence suggests that SGLT2i promote body weight loss, produce a mild reduction in both systolic and diastolic blood pressure, and could decrease disease progression by improving beta-cell insulin secretion and insulin sensitivity in peripheral tissues, associated with a reduction in plasma glucose concentration.",
  "reading_complete" : "2020-08-02T08:42:32Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-02T08:41:50Z",
  "trigger" : "decrease",
  "evidence" : [ "SGLT2i promote body weight loss, produce a mild reduction in both systolic and diastolic blood pressure, and could decrease disease progression by improving beta-cell insulin" ],
  "pmc_id" : "5458028",
  "score" : 0
}